Mirum Pharmaceuticals, Inc. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
Mirum Pharmaceuticals, Inc. (MIRM) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2023-11-02
- Mirum Pharmaceuticals, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2023-09-30 was $0.00.
- Mirum Pharmaceuticals, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2023-06-30 was $0.00.
- Mirum Pharmaceuticals, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2023-03-31 was $0.00.
- Mirum Pharmaceuticals, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for the quarter ending 2022-12-31 was $0.00.
- Mirum Pharmaceuticals, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2022 was $0.00.
- Mirum Pharmaceuticals, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2021 was $0.00.
- Mirum Pharmaceuticals, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2020 was $0.00.
- Mirum Pharmaceuticals, Inc. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2019 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 3 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 6 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 9 month | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $0.00 derived: sum of 3 quarters · filed 2023-08-07 | $0.00 derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2023-05-04 | $0.00 derived: sum of 3 quarters · filed 2023-11-02 | $0.00 derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 derived: sum of 3 quarters · filed 2023-11-02 | $0.00 10-K · filed 2023-03-08 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $0.00 derived: sum of 2 quarters · filed 2023-11-02 | $0.00 10-Q · filed 2023-11-02 | $0.00 derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | $0.00 derived: sum of 3 quarters · filed 2023-08-07 | $0.00 derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-04 | $0.00 derived: sum of 2 quarters · filed 2023-05-04 | $0.00 derived: sum of 3 quarters · filed 2023-05-04 | $0.00 derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $0.00 derived: sum of 2 quarters · filed 2023-03-08 | $0.00 derived: sum of 3 quarters · filed 2023-03-08 | $0.00 10-K · filed 2023-03-08 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $0.00 derived: sum of 2 quarters · filed 2022-11-09 | $0.00 10-Q · filed 2022-11-09 | $0.00 derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $0.00 10-Q · filed 2022-08-04 | $0.00 derived: sum of 3 quarters · filed 2022-08-04 | $0.00 derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2022-05-05 | $0.00 derived: sum of 3 quarters · filed 2022-05-05 | $0.00 derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | $0.00 derived: sum of 2 quarters · filed 2022-03-09 | $0.00 derived: sum of 3 quarters · filed 2022-03-09 | $0.00 10-K · filed 2022-03-09 |
| 2020-09-30 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $0.00 10-Q · filed 2021-11-15 | $0.00 derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2021-08-05 | $0.00 derived: sum of 3 quarters · filed 2021-05-06 | $0.00 derived: sum of 4 quarters · filed 2021-05-06 |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | $0.00 derived: sum of 2 quarters · filed 2021-05-06 | $0.00 derived: sum of 3 quarters · filed 2021-05-06 | $0.00 derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $0.00 derived: sum of 2 quarters · filed 2021-03-09 | $0.00 derived: sum of 3 quarters · filed 2021-03-09 | $0.00 10-K · filed 2021-03-09 |
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 | $0.00 derived: sum of 2 quarters · filed 2020-11-12 | $0.00 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $0.00 10-Q · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |